Re: Farmas USA
MDCO
Catalizadores en breve..cuidadin
https://biopharmcatalyst.com/calendars/fda-calendar
MDCO
PCSKsi - ORION-1
Atherosclerotic cardiovascular disease (ASCVD)
Phase 2 11/15/2016
Phase 2 interim analysis and possibly top-line data to be presented at a late breaking session at the AHA Scientific Sessions on November 15, 2016.
MDCO
MDCO-216 - MILANO-PILOT
Acute coronary syndrome (ACS)
Phase 2 11/15/2016
Phase 2 interim analysis conducted by DSMB determined that the trial should proceed. Data to be presented at a late breaking session at the AHA Scientific Sessions on November 15, 2016
MDCO
CARBAVANCE
Complicated urinary trace infections (cUTI)
NDA Filing 03/31/2017
Phase 3 data met endpoints June 2016. NDA filing due early 2017